Cyprotex Limited was founded in 1999 as an operating division of Medeval Limited, to develop the concept of predictive ADME, predictive toxicology and Drug-to-Drug Interaction (DDI) screening and to provide its customers with a fully automated mass compound high-throughput screening service.